1. Hyams J, Markowitz J, Lerer T, et al. The natural history of pediatric Crohn's disease: a population-based cohort study. Am J Gastroenterol. 2019;114(2):295-300.
[2]
2. Levine A, Koletzko S, Turner D, et al. ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2020;70(5):579-594.
[3]
3. Consolaro A, Giannini G, Ferrari C, et al. Arthritis in children with inflammatory bowel disease: a single-center experience. Rheumatology. 2021;60(3):1428-1435.
[4]
4. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2018;155(5):1585-1595.
[5]
5. D'Arcangelo G, Pofi E, Grossi A, et al. Musculoskeletal manifestations in pediatric inflammatory bowel disease. Front Pediatr. 2022;10:856789.
[6]
6. Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease: from bench to bedside. Nat Rev Rheumatol. 2019;15(6):323-334.
[7]
7. Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr. 2022;74(4):516-534.
[8]
8. Church PC, Guan J, Walters TD, et al. Infliximab maintains durable response and allows for withdrawal in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2021;72(5):684-690.